Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alto Neuroscience, Inc. (ANRO : NYSE)

• Company Description    Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company. Its clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia and other mental health conditions. Alto Neuroscience Inc. is based in LOS ALTOS, Calif. Number of Employees: 76

• Price / Volume Information    Yesterday's Closing Price: $2.58 Daily Weekly Monthly 20 Day Moving Average: 350,734 shares Shares Outstanding: 27.07 (millions) Market Capitalization: $69.85 (millions) Beta: 1.65 52 Week High: $17.55 52 Week Low: $1.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.31% 1.36% 12 Week 14.16% -3.98% Year To Date -39.01% -42.88%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 650 CASTRO STREET SUITE 450 - MOUNTAIN VIEW,CA 94041 USA ph: 650-200-0412 fax: - investors@altoneuroscience.com http://www.altoneuroscience.com

• General Corporate Information    Officers Amit Etkin - Chief Executive Officer; President and Chairman Nicholas Smith - Chief Financial Officer Christopher Nixon Cox - Director Andrew Dreyfus - Director Husseini Manji - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 02157Q109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 27.07 Most Recent Split Date: (:1) Beta: 1.65 Market Capitalization: $69.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.64 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.39 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.50 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 30.26% vs. Previous Quarter: 5.36% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -39.35 12/31/24 - -35.64 ROA 06/30/25 - - 03/31/25 - -33.86 12/31/24 - -31.65 Current Ratio 06/30/25 - - 03/31/25 - 22.53 12/31/24 - 16.92 Quick Ratio 06/30/25 - - 03/31/25 - 22.53 12/31/24 - 16.92 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 5.14 12/31/24 - 5.62 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.15 12/31/24 - 0.08 Debt-to-Capital 06/30/25 - - 03/31/25 - 13.20 12/31/24 - 7.09

Powered by Zacks Investment Research ©